Xention appoints chief medical officer
Xention, the Cambridge, UK-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, has appointed Dr Patrick Round as chief medical officer and head of development.
Xention, the Cambridge, UK-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, has appointed Dr Patrick Round as chief medical officer and head of development.
Dr Round has broad development experience in both biotech and pharma, most notably as senior vice president at Cambridge Antibody Technology (CAT).
Previously, Dr Round was director of development at Celltech r&d, director of clinical development at Glaxo Wellcome and clinical project manager at Novo Nordisk Pharmaceuticals.